ALEC
NASDAQAlector Inc.
News · 26 weeks44+140%
2026-04-192026-10-11
Mix2190d
- Other7(33%)
- SEC Filings7(33%)
- Insider7(33%)
Latest news
25 items- SECSEC Form 424B5 filed by Alector Inc.424B5 - Alector, Inc. (0001653087) (Filer)
- SECSEC Form 8-K filed by Alector Inc.8-K - Alector, Inc. (0001653087) (Filer)
- SECSEC Form FWP filed by Alector Inc.FWP - Alector, Inc. (0001653087) (Subject)
- PRAlector Announces Pricing of Underwritten OfferingSOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (("Alector, NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000.00 before deducting the underwriting discounts and commissions and other estimated offering
- INSIDERSEC Form 4 filed by Alector Inc.4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERSEC Form 4 filed by Alector Inc.4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERSEC Form 4 filed by Alector Inc.4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form 8-K filed by Alector Inc.8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineAgenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company's wholly owned ABC blood-brain barrier platform and programs in its ABC-enabled pipeline. Details of the webinar are as follows: Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration Tuesday, October 13, 2026, at 8:00
- PRBiotech Brainiacs and BreakthroughsDENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotech market is producing a powerful mix of catalysts, with Alector (NASDAQ:ALEC) and NeOnc Technologies (NASDAQ:NTHI) putting the spotlight on the brain while Vaxcyte (NASDAQ:PCVX) delivers a potentially market-shifting Phase 3 vaccine readout. Alector Lands A $1.27 Billion Genentech Deal Alector (NASDAQ:ALEC) turned its AL050 Parkinson’s disease program into a potential $1.27 billion opportunity through an exclusive global licensing agreement with Genentech, a member of the Roche Group (OTCQX: RHHBY). The deal provides Alector with $100 million upfront, potential milestone payments of up to $1.17 billion, and tiered
- SECAlector Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative DiseasesAlector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform Alector to receive $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as well as tiered royalties on net sales SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it has entered into an exclusive global licensing agreement with Gene
- SECSEC Form SCHEDULE 13G filed by Alector Inc.SCHEDULE 13G - Alector, Inc. (0001653087) (Subject)
- INSIDERChief Executive Officer Rosenthal Arnon sold $193,473 worth of shares (72,606 units at $2.66), decreasing direct ownership by 3% to 2,294,600 units (SEC Form 4) to cover taxes4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay sold $77,948 worth of shares (29,251 units at $2.66), decreasing direct ownership by 8% to 350,649 units (SEC Form 4) to satisfy withholding obligation4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $24,666 worth of shares (9,446 units at $2.61) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 106,015 units (SEC Form 4) to cover taxes4 - Alector, Inc. (0001653087) (Issuer)
- PRAlector to Participate in Upcoming Healthcare ConferencesSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York)Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat Morgan Stanley 24th Annual Global Healthcare Conference (New York, New York)Tuesday, September 15, 2026, at 7:00 a.m. ET, fireside chat A live webcast of each fireside chat will be available on the "Events & Presentations" page within the Investors secti
- INSIDERChief Executive Officer Rosenthal Arnon gifted 1,050,000 shares and received a gift of 1,050,000 shares (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form 10-Q filed by Alector Inc.10-Q - Alector, Inc. (0001653087) (Filer)
- SECAlector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector Reports Second Quarter 2026 Financial Results and Provides Business UpdateAdvancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)). $172.8 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression o
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace was granted 20,000 shares, increasing direct ownership by 21% to 115,461 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECAlector Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - Alector, Inc. (0001653087) (Filer)
- INSIDERDirector Scheller Richard H was granted 28,700 shares, increasing direct ownership by 27% to 134,899 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERDirector Yaffe Kristine was granted 28,700 shares, increasing direct ownership by 30% to 124,109 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
ALEC FAQ
7 questionsWhat does Alector Inc. do?
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment...Where does ALEC stock trade?
Alector Inc. (ALEC) is listed on NASDAQ.What sector and industry is ALEC in?
Alector Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Alector Inc. go public?
Alector Inc. (ALEC) completed its IPO in 2019.What are analysts saying about ALEC?
Alector Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-15. Recent price targets range from $150.00 to $600.00.What companies are similar to ALEC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ALEC side-by-side with any of them on Quantisnow.How can I track ALEC on Quantisnow?
Quantisnow aggregates Alector Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALEC to receive live email and push alerts on every new disclosure.